Von Willebrand Disease Market (Updated Version Available)

Key Market Overview:

Von Willebrand Disease Market size was valued at USD 491.87 Million in 2022, registering a CAGR of 6.2% during the forecast period (2023-2030), and the market is projected to be worth USD 793.55 Million by 2030.

Von Willebrand disease refers to a bleeding disorder in which the patients blood is unable to clot properly and it is a lifelong disease. The patients with the disease have minimum levels of von Willebrand factor, which is a protein that enables blood clots. Von Willebrands is an incurable type of disease. However, with treatment and self-care, including desmopressin, replacement therapies, and others most people with Von Willebrand disease can lead active lifestyles. The increasing prevalence of Von Willebrand disease is a prime factor accelerating the growth of the market.

For instance, according to the National Library of Medicine (NLM), in 2023 approximately 0.6% to 1.3% of the global population is suffering from Von Willebrand disease (VWD). Furthermore, the prevalence of Von Willebrand disease (VWD) was about 10 per 100,000. Thus, the increasing prevalence of Von Willebrand disease (VWD) is accelerating the demand for Von Willebrand disease treatments to ease the bleeding which driving the growth of the market.

Von Willebrand Disease Market Report Coverage:

Report Attributes	Report Details
Study Timeline	2017-2030
Market Size in 2030 (USD Million)	793.55 Million
CAGR (2023-2030)	6.2%
Base Year	2022
By Type	Type 1, Type 2, Type 3, and Acquired VWD
By Tretament Type	Desmopressin, Replacement Therapies, Clot-stabilizing Medications, and Others
By Geography	Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia] Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey] North America [United States, Canada, Mexico] Middle East & Africa [GCC, North Africa, South Africa] South America [Brazil, Argentina, Columbia, Chile, Peru]
Key Players	CSL Behring, Grifols, S.A., Takeda Pharmaceutical Company Ltd, Bio Products Laboratory Ltd., Sanofi SA, Bayer AG, Octapharma AG, Novo Nordisk A/S, Nufactor, Inc., and BioMedica Diagnostics

Request Sample

Market Dynamics:

Driver:

Global players in the Von Willebrand disease treatment industry are increasingly leveraging their technological potential for the development of a new range of Von Willebrand disease treatments to increase their product offerings in the global market. As a result of this, Von Willebrand disease manufacturers, having their presence at the global level, are investing in the development of new methods with updated technological advancements to ensure the development of new Von Willebrand disease treatments. Thus, the launch of a new Von Willebrand disease treatment with upgraded technology is leading to the growth of the Von Willebrand disease market.

For illustration, in February 2023, Sanofi received FDA approval for ALTUVIIIO as a treatment for Von Willebrands disease. Hence, the increasing new technological developments of Von Willebrand disease treatment by various global companies to enhance the effectiveness of drugs is a crucial factor fostering the growth of the global Von Willebrand disease treatment market.

Restraint:

The presence of contamination, the potential of foreign substances, government interventions, non-sterility, and others are leading to the recall of the Von Willebrand disease treatment product range.

For instance, in October 2020, Ferring Pharmaceuticals, headquartered in France globally recalled Desmopressin Therapies utilized for the treatment of Von Willebrand disease, owing to the higher concentrations of desmopressin substances. Thus, due to the above factors major players in the global Von Willebrand disease treatment market are recalling various Von Willebrand disease treatment products. The recall of Von Willebrand disease treatment products will impact the revenue growth of various companies, thereby posing a major bottleneck for market growth in the upcoming year.

Opportunities:

The increasing partnerships between leading players dealing in Von Willebrand disease treatment, investment in research & development activities, and others are some of the prominent factors prompting the global Von Willebrand disease treatment manufacturers to develop a new range of drugs. This factor is leading to the increasing pipeline for the treatment of Von Willebrands disease. For instance, Sanofi, a leading pharmaceutical manufacturer in France is developing efanesoctocog alfa (BIV001), a therapy for the treatment of type 2 and type 3 Von Willebrand disease. Thus, the increasing pipeline for the treatment of Von Willebrand disease will create a potential growth opportunity for the market at the global level.

Market Segmentation:



By Types

The type segment is classified into type 1, type 2, type 3, and acquired VWD. In 2022, the type 1 segment accounted for the highest market share in the Von Willebrand disease market. Type 1 Von Willebrand disease is the mildest form of Von Willebrand disease (VWD), in which a patient has lower levels of Von Willebrand disease. Furthermore, a person with Type 1 form of Von Willebrand disease might also have low levels of factor VIII, which is a type of protein for blood clotting. For instance, according to the Centers for Disease Control and Prevention, approximately 85% of patients suffering from Von Willebrand disease (VWD) have type 1 disease. Thus, due to the increasing prevalence of type 1 Von Willebrand disease, the utilization of treatments is increasing to stimulate the body to release more of the Von Willebrand factor, this, in turn, is driving the market growth.

However, type 2 is expected to grow at the fastest CAGR during the forecast period due to the increasing research and development activities for the commercialization of various Von Willebrand disease treatments for type 2.

By Treatment Type

The treatment type segment is categorized into desmopressin, replacement therapies, clot-stabilizing medications, and others. Desmopressin is utilized for preventing bleeding in patients suffering from Von Willebrands disease (VWD). The desmopressin efficiently releases Von Willebrands antigen from the cells and platelets that line the blood vessels. Additionally, the desmopressin medication works quickly, with a superior effect in 60 minutes. The effect lasts from the range of 8 to 12 hours or longer. Thus, due to the above benefits, the adoption of desmopressin is increasing for the treatment of Von Willebrand disease (VWD), thereby driving the growth of the growth.

However, the replacement therapies segment is expected to be the fastest-growing segment over the forecast period owing to the development of a new range of therapies. For instance, in December 2022, Vega Therapeutics, Inc., headquartered in the United States announced its plans for the development of VGA039, a replacement treatment for Von Willebrand disease. Thus, the ongoing development of various replacement therapies for the efficient treatment of Von Willebrand disease (VWD) will boost segmental growth in the upcoming years.

By Region:

By region, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. In 2022, North Ameirca accounted for the highest market share in the Von Willebrand disease market due to the increasing development of a new range of Von Willebrand disease treatments. For instance, in February 2023, Octapharma USA applied for FDA approval for a while VWD Prophylaxis Supplement. The product is utilized for the treatment of Von Willebrand disease (VWD). Thus, the development of a new range of Von Willebrand disease (VWD) treatments will boost the growth of the market during the projected forecast period.



Nevertheless, Asia Pacific is expected to be the fastest-growing region over the forecast period due to the presence of major players in the market, the development of new Von Willebrand disease (VWD) treatments, and others.

Von Willebrand Disease Market Competitive Landscape:

The Von Willebrand disease market is highly competitive, with several large players and numerous small and medium-sized enterprises. These companies have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships. The key players in the market include-

• CSL Behring
• Grifols, S.A.
• Takeda Pharmaceutical Company Ltd
• Bio Products Laboratory Ltd.
• Sanofi SA
• Bayer AG
• Octapharma AG
• Novo Nordisk A/S
• Nufactor, Inc.
• BioMedica Diagnostics

Recent Developments

• In January 2022, Takeda Pharmaceutical Company Limited., a Japan-based pharmaceuticals company announced the FDA approval for the VONVENDI for the treatment of type 3 Von Willebrand disease (VWD).